Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

The transition from myelodysplastic neoplasm to secondary acute myeloid leukemia is revealed by molecular analysis, while functional drug screening demonstrates novel sensitivity patterns with clinical implication

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJieya WuMAMichelle AfkhamiEJErlie Jiang

Discussion

Loading...

Member takes

Overview

Functional drug screening highlights new agents affecting drug sensitivity in myelodysplastic neoplasm and secondary acute myeloid leukemia.

Key Points

  • This research aims to analyze molecular changes during the transition from myelodysplastic neoplasm to secondary acute myeloid leukemia and identify effective treatments.
  • Collected longitudinal sequencing data from 22 patient samples
  • Developed a high throughput drug screen using multicolor flow cytometry
  • Analyzed mutation data and drug responses in MDS and sAML samples
  • Calculated drug sensitivity scores to identify effective agents
  • Utilized statistical methods to compare differences in drug sensitivity between MDS and sAML.
  • Identified different clonal evolution patterns in MDS progressing to sAML
  • Found significant differences in variant allele frequency for mutations such as FLT3, NRAS between MDS and sAML
  • Determined high drug sensitivity for agents like venetoclax and trametinib in MDS patients
  • Validated specific agents with potential for improving outcomes in high-risk MDS and sAML patients.
  • Observed responses indicating potential use of hypomethylating agents in treatment.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5dehttps://doi.org/10.1182/blood-2025-4328
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.2026
  2. 2Multiomics-guided ex vivo drug sensitivity testing in Relapsed/Refractory Acute Myeloid Leukemia2025
  3. 3Molecular subclusters across the continuum of myelodysplastic neoplasms and acute myeloid leukaemia define distinct clinical entities2025
  4. 4Longitudinal genomic and cytogenetic dynamics in myelodysplastic syndromes (MDS): Insights into clonal evolution and disease progression2025
  5. 5Clonal dynamic changes during the progression of myelodysplastic neoplasms to secondary acute myeloid leukemia: a paired-sample comparison2026